跳至主要内容
临床试验/EUCTR2013-004567-30-AT
EUCTR2013-004567-30-AT进行中(未招募)不适用

A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD)

Boehringer Ingelheim RCV GmbH & Co KG0 个研究点目标入组 70 人开始时间: 2014年3月12日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Newly diagnosed men and women with unilateral subfoveal choroideal neovascularization secondary to age-related macular degeneration
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 50

排除标准

  • Additional eye disease that could compromizse best corrected visual acuity, such as uncontrolled glaucoma

研究者

相似试验

进行中(未招募)
1 期
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratioewly diagnosed unilateral wet age-related macular degeneration (wAMD)MedDRA version: 17.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853
EUCTR2013-004567-30-DEBoehringer Ingelheim Pharma GmbH & Co. KG30
进行中(未招募)
不适用
A 4 week study with BI 144807 in patients >= 50 years with wet age related macular degeneratiopatients with newly diagnosed, unilateral, wet Are-Related Macular DegenerationMedDRA version: 17.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 100000004853
EUCTR2013-004567-30-HUBoehringer Ingelheim RCV GmbH & Co KG70
进行中(未招募)
不适用
A study to compare pediatric patients ages 12-17 to adult patients ages 18-64 and see how much study drug SPRIX is in the blood, how safe the study drug SPRIX is and how well it decreases pain after surgery.
EUCTR2013-000938-35-PLuitpold Pharmaceuticals, Inc.59
进行中(未招募)
不适用
An open label multicenter study to assess the pharmacokinetic, tolerability and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension iPAHTreatment of pulmonary arterial hypertension in children.MedDRA version: 6.1Level: PTClassification code 10037405
EUCTR2004-005157-63-ITACTELION PHARMACEUTICALS ITALIA35
进行中(未招募)
不适用
A Phase 1 study of the body and tumour effects of CUDC-101 in HER2 positive breast cancer patients
EUCTR2012-003064-47-GBCuris, Inc.